drugset / Trial / NCT05985954
Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
Phase 1
Recruiting
27 enrolled
M.D. Anderson Cancer Center
BioMed Valley Discoveries, Inc · collabEli Lilly and Company · collab
RandomizedSingle-groupOpen-labelTreatment
Summary
To find the recommended dose of ulixertinib that can be given in combination with cetuximab and/or encorafenib to patients with unresectable/metastatic CRC and who have received EGFR or BRAF-directed therapy in the past.
Timeline
- Start
- 2024-01-18
- Primary completion
- 2028-03-28
- Completion
- 2028-03-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Encorafenib | Small molecule | — | Oral |
| Subject | Ulixertinib | Small molecule | — | Oral |
| Background | Cetuximab | Monoclonal antibody | — | Intravenous |